<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28457" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Retinitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Nikita</given-names>
          </name>
          <aff>PGIMER, Chandigarh</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nikita Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28457.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Retinitis, also known as inflammation of the retina, often accompanies systemic medical conditions, particularly infections and inflammatory diseases, posing a risk of vision loss. Infections by microbes such as cytomegalovirus,&#x000a0;<italic toggle="yes">Toxoplasma gondii</italic>, and&#x000a0;<italic toggle="yes">Candida</italic>&#x000a0;are common causes, with risk factors including maternal infections, exposure to endemic areas, or immunocompromised states. Genetic factors can also contribute, as observed in Beh&#x000e7;et disease.&#x000a0;</p>
        <p>Numerous potential underlying causes of retinitis exist, and clinical information dictates diagnostic testing. The evaluation may include serologic testing for autoimmune or infectious diseases, polymerase chain reaction testing of intraocular fluid for various pathogens, ophthalmologic examinations, fluorescein fundus angiography, and optical coherence tomography.&#x000a0;</p>
        <p>Management strategies involve topical or systemic medications tailored to the specific condition and patient needs, including antivirals or antibiotics, corticosteroids, and immunosuppressive agents. Regular monitoring is crucial to assess treatment response and adjust therapy as necessary. This topic discusses the etiology, pathophysiology, evaluation, and management of retinitis, providing healthcare professionals with knowledge of the diverse etiologies and presentations. By staying informed about the varying presentations and management approaches tailored to specific causes, clinicians can optimize patient care to prevent vision loss and safeguard ocular health.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the various underlying causes of retinitis, including infectious and inflammatory diseases.</p></list-item><list-item><p>Implement appropriate diagnostic procedures, including funduscopic examination, imaging studies, and laboratory tests, to confirm the etiology of retinitis.</p></list-item><list-item><p>Apply evidence-based treatment strategies tailored to the specific etiology of retinitis.</p></list-item><list-item><p>Collaborate with other healthcare professionals to optimize multidisciplinary care for patients with retinitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28457&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28457">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28457.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Retinitis, characterized by inflammation of the retina, frequently occurs in association with other systemic medical conditions, especially infections and inflammatory diseases, posing a risk of vision loss.&#x000a0;The retina, situated at the back of the eye, transmits images as electrical impulses through the optic nerve to the brain, allowing sight.&#x000a0;</p>
        <p>Infectious agents, inflammatory diseases, and hypersensitivity reactions may all cause inflammation in various areas of the eye. The uvea comprises the iris, ciliary body, and choroid. Anterior uveitis, also known as iritis, involves leukocytes in the anterior chamber, whereas iridocyclitis includes inflammation of the adjacent ciliary body. Posterior uveitis involves inflammation of the choroid or retina and includes chorioretinitis, retinochoroiditis, retinitis, and neuroretinitis.</p>
        <p>Microbes&#x000a0;such as human herpesvirus 5 (HSV-5) or cytomegalovirus (CMV),&#x000a0;<italic toggle="yes">Toxoplasma gondii</italic>,&#x000a0;and&#x000a0;<italic toggle="yes">Candida</italic>&#x000a0;are responsible for infectious retinitis. Significant risk factors include active maternal infection during pregnancy or childbirth, exposure to endemic areas, or an immunocompromised state. Retinitis can result from infections in heart valves, the gastrointestinal tract, and the urinary tract, as well as among individuals who use intravenous drugs. Retinitis may be the sole manifestation of autoimmune diseases such as Beh&#x000e7;et disease. The consequences of retinitis vary depending on the age, location, and immune status. Affected patients may present with isolated retinitis or in conjunction with choroidal involvement, such as retinochoroiditis or chorioretinitis, requiring clinicians to tailor management strategies based on the specific cause to prevent vision loss and protect the contralateral eye.</p>
      </sec>
      <sec id="article-28457.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Retinitis<bold>&#x000a0;</bold>may be idiopathic or related to infectious, inflammatory, or underlying genetic causes. Posterior uveitis is associated with various human leukocyte antigen (HLA) phenotypes. Birdshot chorioretinitis, linked to HLA-29 in 95% of patients, manifests with chorioretinal lesions resembling birdshot pellets. Uveitis and inflammatory bowel disease co-occur in 45% of patients with HLA-B27. Vogt-Koyanagi-Harada syndrome exhibits a robust HLA class II association, particularly with the HLA-D locus and DR4 allele.</p>
        <p>
<bold>Infectious Causes</bold>
</p>
        <p>Infectious causes include bacterial, spirochetal, viral, fungal, and parasitic diseases.</p>
        <p><bold>Parasitic disease:&#x000a0;</bold><italic toggle="yes">T gondii</italic>&#x000a0;is a widely distributed intracellular protozoan parasite. Humans and other mammals act as intermediate hosts, whereas cats are the definitive hosts for&#x000a0;<italic toggle="yes">T gondii.&#x000a0;</italic>Uveitis&#x000a0;caused by&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;occurs as either a reactivation of a congenitally acquired infection or a new infection.<xref ref-type="bibr" rid="article-28457.r1">[1]</xref></p>
        <p>
<bold>Viral disease:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cytomegalovirus:&#x000a0;Posterior uveitis resulting from CMV infection is&#x000a0;predominantly observed in immunocompromised patients and may result in blindness.<xref ref-type="bibr" rid="article-28457.r2">[2]</xref>&#x000a0;Although uncommon in North America and Europe and more common in Southeast Asia, CMV may rarely cause anterior uveitis in immunocompetent patients.</p>
          </list-item>
          <list-item>
            <p>Herpes virus:&#x000a0;Both HSV<italic toggle="yes">-</italic>1&#x000a0;and&#x000a0;HSV<italic toggle="yes">-</italic>2&#x000a0;and<italic toggle="yes">&#x000a0;</italic>HSV-3<italic toggle="yes">&#x000a0;</italic>or varicella zoster virus&#x000a0;(VZV)<italic toggle="yes">&#x000a0;</italic>may cause acute retinal necrosis.<xref ref-type="bibr" rid="article-28457.r3">[3]</xref>&#x000a0;In addition, ocular HSV may cause keratitis, conjunctivitis, or blepharitis. Neonates may develop chorioretinitis due to disseminated HSV infection. CMV and rarely&#x000a0;Epstein-Barr virus&#x000a0;(EBV) may also cause acute retinal necrosis. Progressive outer retinal necrosis (PORN) is a clinical variant of necrotizing herpetic retinopathy caused by VZV and occasionally CMV and noted in patients with AIDS.<xref ref-type="bibr" rid="article-28457.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>West Nile virus:<bold>&#x000a0;</bold>Chorioretinitis and retinal vasculitis are common complications associated with West Nile virus infection. Many affected patients may be asymptomatic.</p>
          </list-item>
          <list-item>
            <p>Measles virus:<bold><italic toggle="yes">&#x000a0;</italic></bold>Around 7&#x000a0;to 10 years after a measles infection, some patients may develop subacute sclerosing panencephalitis, a fatal neurodegenerative disease.&#x000a0;Subacute sclerosing panencephalitis is caused by persistent infection with a genetically altered form of the measles virus, primarily affecting children and young adults.</p>
          </list-item>
          <list-item>
            <p>Dengue virus:&#x000a0;Dengue fever can cause retinitis and foveolitis.</p>
          </list-item>
          <list-item>
            <p>Chikungunya virus:&#x000a0;Infection with the chikungunya virus results in various anterior and posterior segment manifestations, with iridocyclitis and retinitis being the most common.<xref ref-type="bibr" rid="article-28457.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Bacterial disease:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Syphilis:&#x000a0;Caused by the bacterium&#x000a0;<italic toggle="yes">Treponema pallidum</italic>, syphilis is a leading cause of posterior uveitis. Ocular manifestations can occur in all stages of the disease, although they are more prevalent in secondary and late syphilis.<xref ref-type="bibr" rid="article-28457.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Tuberculosis:<bold>&#x000a0;</bold><italic toggle="yes">Mycobacterium tuberculosis&#x000a0;</italic>is an uncommon cause of posterior uveitis in the United States, but clinicians should consider tuberculosis when uveitis worsens with glucocorticoid therapy or in patients with a history of active tuberculosis, incarceration, immunosuppression, or granulomatous&#x000a0;inflammation.</p>
          </list-item>
          <list-item>
            <p>Cat scratch disease:&#x000a0;Trauma from a cat scratch, cat bite, or contact with flea feces may cause an infection with&#x000a0;<italic toggle="yes">Bartonella henselae</italic>, a gram-negative hemotrophic bacillus. Ocular symptoms are generally unilateral.<xref ref-type="bibr" rid="article-28457.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Rocky Mountain spotted fever:&#x000a0;A zoonosis caused by<bold>&#x000a0;</bold><italic toggle="yes">Rickettsia</italic><bold>&#x000a0;</bold><italic toggle="yes">rickettsii&#x000a0;</italic>and transmitted to humans by the bite of contaminated ticks, 30% of patients with Rocky Mountain spotted fever (RMSF) develop retinitis. In addition, some may develop retinal vascular involvement and optic disc changes.<xref ref-type="bibr" rid="article-28457.r8">[8]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lyme disease:&#x000a0;A vector-borne zoonosis caused by the bite of an&#x000a0;<italic toggle="yes">Ixodes</italic>&#x000a0;tick infected by the bacteria&#x000a0;<italic toggle="yes">Borrelia burgdorferi</italic>, retinitis is a rare presentation noted in the late disseminated stage of the disease.<xref ref-type="bibr" rid="article-28457.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Histoplasmosis:<bold>&#x000a0;</bold>Patients&#x000a0;residing in areas endemic to&#x000a0;<italic toggle="yes">Histoplasma capsulatum</italic>, including states that contain the Ohio and Mississippi river valleys, may develop ocular histoplasmosis syndrome, potentially leading to chorioretinitis.<xref ref-type="bibr" rid="article-28457.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Endogenous endophthalmitis or metastatic endophthalmitis:&#x000a0;Endogenous microbes are an additional potential infectious source.<xref ref-type="bibr" rid="article-28457.r11">[11]</xref>&#x000a0;Approximately 50% are bacterial, and 50% are fungal. The most frequently identified causative bacteria in North America and Europe are&#x000a0;<italic toggle="yes">Staphylococcus aureus&#x000a0;</italic>and&#x000a0;<italic toggle="yes">Streptococcus pneumoniae</italic>,<italic toggle="yes">&#x000a0;</italic>whereas&#x000a0;<italic toggle="yes">Klebsiella pneumoniae&#x000a0;</italic>is&#x000a0;more prevalent in East Asia. Risk factors include diabetes, liver disease, cardiac disease, malignancy, indwelling catheters, and intravenous drug use.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Fungal disease:&#x000a0;</bold><italic toggle="yes">Candida</italic>&#x000a0;and&#x000a0;<italic toggle="yes">Aspergillus&#x000a0;</italic>are the most common causes of fungal endogenous chorioretinitis and endophthalmitis. Immunocompromised patients are at particular risk of developing the disease.&#x000a0;<italic toggle="yes">Histoplasma</italic>&#x000a0;may result in presumed ocular histoplasmosis syndrome, occurs in immunocompetent individuals, and is recognized by the presence of peripapillary atrophy and multiple atrophic chorioretinal scars without vitreous or aqueous humor inflammation.</p>
        <p><bold>Helminthic disease:&#x000a0;</bold>Toxocariasis caused by the nematode&#x000a0;<italic toggle="yes">Toxocara canis</italic>&#x000a0;is a rare yet significant contributor to posterior uveitis in infants and young children.<xref ref-type="bibr" rid="article-28457.r12">[12]</xref>&#x000a0;Ocular toxocariasis can present as a posterior pole or peripheral granuloma, with few patients developing dense vitritis mimicking endophthalmitis. Diffuse unilateral subacute neuroretinitis is an ocular infectious condition resulting from a worm, the complete understanding of whose etiology remains elusive, potentially resulting in visual impairment and blindness.</p>
        <p>
<bold>Post-Fever Retinitis</bold>
</p>
        <p>Post-fever retinitis denotes varied retinal manifestations after a systemic febrile illness caused by bacteria, viruses, or protozoa. These manifestations typically appear 2 to 4 weeks after the onset of fever in immunocompetent patients. Symptoms improve with corticosteroids, implying a potential immunological origin. Posterior segment manifestations encompass focal and multifocal patches of retinitis, potential optic nerve engagement, serous macular detachment, macular edema, and localized retinal vessel involvement characterized by vessel beading, tortuosity, and perivascular sheathing.</p>
        <p>
<bold>Noninfective Causes</bold>
</p>
        <p>Systemic inflammatory diseases are also associated with uveitis. The majority of patients with Beh&#x000e7;et disease develop uveitis, along with occlusive vasculitis as a characteristic feature. Additional systemic diseases include sarcoidosis, systemic lupus erythematosus, eosinophilic granulomatosis with polyangiitis, psoriatic arthritis, inflammatory bowel disease, Sj&#x000f6;gren syndrome, and Vogt-Koyanagi-Harada syndrome.</p>
      </sec>
      <sec id="article-28457.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Epidemiological information depends on various factors, including the underlying etiology, the patient's immune status, and geographical location.&#x000a0;</p>
        <p>
<bold>Cytomegalovirus</bold>
</p>
        <p>CMV retinitis predominantly affects immunocompromised individuals, such as neonates, patients with AIDS, and organ transplant recipients. Around 4% of patients who undergo hematopoietic stem cell transplantation develop CMV retinitis. CMV is a leading opportunistic ocular infection in patients with AIDS, particularly when CD4 T-lymphocyte counts drop below 50 cells/&#x000b5;L.<xref ref-type="bibr" rid="article-28457.r13">[13]</xref>&#x000a0;The introduction of highly active antiretroviral therapy has reduced the current prevalence of CMV retinitis from 40% to 20%. The incidence rate of retinitis in the uninvolved eye has decreased by 46%. The incidence rate of CMV retinitis following highly active antiretroviral therapy&#x000a0;is 0.36/100 person-years, with an&#x000a0;average onset age between 20 and 50.</p>
        <p>
<bold>Toxoplasmosis</bold>
</p>
        <p>T<italic toggle="yes"> gondii</italic>&#x000a0;is the most common pathogenic cause of posterior uveitis in immunocompetent hosts.<italic toggle="yes">&#x000a0;</italic>Three genotypes of&#x000a0;<italic toggle="yes">T gondii&#x000a0;</italic>exist. Genotype II is most prevalent in Europe and the United States. Approximately 80% to 90% of patients infected with genotype II remain asymptomatic. Genotype I is most prevalent in South and Central America and, more frequently, causes systemic symptoms. In areas&#x000a0;such as Brazil, the seropositive rate for toxoplasmosis is nearly 80%, with 6% to 18% of immunocompetent individuals developing ocular symptoms. Toxoplasma retinochoroiditis accounts for 30% to 55% of cases of posterior uveitis in high&#x000a0;<italic toggle="yes">T gondii&#x000a0;</italic>endemic regions of the United States and European nations.<xref ref-type="bibr" rid="article-28457.r14">[14]</xref></p>
        <p>
<bold>Human Herpes Virus</bold>
</p>
        <p>Keratitis is the most prevalent form of ocular disease due to HSV and is a significant cause of blindness worldwide. In neonates, HSV keratitis can lead to complications such as corneal scarring, cataracts, and chorioretinitis. Skin, eye, and mouth disease accounts for approximately 35% to 45% of neonatal HSV cases.</p>
        <p>
<bold>Beh&#x000e7;et Disease</bold>
</p>
        <p>Beh&#x000e7;et disease is more common in men compared to that in women and typically affects young adults. Men are more likely to be affected by ocular involvement and have a worse visual prognosis. The prevalence of Beh&#x000e7;et disease varies geographically, with a higher prevalence observed in countries spanning from eastern Asia to the Mediterranean region.<xref ref-type="bibr" rid="article-28457.r15">[15]</xref>&#x000a0;Estimates from Turkey vary from 80 to 370 cases per 100,000 population. In contrast, prevalence estimates from Japan, Korea, China, and the Middle East vary&#x000a0;from 13 to 20 cases per 100,000 population. The prevalence in the United States varies from 0.12 to 5 cases per 100,000 persons. Uveitis occurs in 60% to 80% of patients with Beh&#x000e7;et disease. Vogt-Koyanagi-Harada syndrome is the second leading cause of uveitis in Japan after Beh&#x000e7;et syndrome.</p>
        <p>
<bold>Rocky Mountain Spotted Fever</bold>
</p>
        <p>RMSF is the most common cause of fatal tick-borne disease in the United States and is endemic in the Southeast, the western South Central region, and selected areas of the Northeast parts of the United States and Central and South America.<xref ref-type="bibr" rid="article-28457.r8">[8]</xref> In endemic areas such as North Carolina, the annual incidence among children aged 5 to 9 is estimated at 42 cases per 100,000. Although White patients experience RMSF more frequently compared to their Black counterparts, Black patients have a higher fatality rate. American Indians face the highest risk of RMSF. Males have a higher rate of infection and a higher mortality rate, with the highest incidence of infection observed between 5 to 9 and 60 to 69. The risk of posterior uveitis with RMSF is low.</p>
        <p>
<bold>Lyme Disease</bold>
</p>
        <p>Lyme disease is endemic in North America and Europe.<xref ref-type="bibr" rid="article-28457.r9">[9]</xref>&#x000a0;A study involving 160 cases of posterior uveitis reveals that Lyme disease accounts for 4.4% of the cases.</p>
        <p>
<bold>Additional Information</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute retinal necrosis affects patients who are immunocompetent or immunosuppressed regardless of age or gender,&#x000a0;accounting&#x000a0;for 5.5% of uveitis cases over a 10-year period.<xref ref-type="bibr" rid="article-28457.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Those at the highest risk of developing ocular histoplasmosis syndrome from&#x000a0;<italic toggle="yes">H capsulatum&#x000a0;</italic>are patients who are immunocompromised, infants, and individuals older than 55.</p>
          </list-item>
          <list-item>
            <p>Approximately 2% to 9% of patients with inflammatory bowel disease and 7% of patients with systemic&#x000a0;lupus erythematosus may develop uveitis.</p>
          </list-item>
          <list-item>
            <p>Ocular toxocariasis primarily affects older children and adolescents.</p>
          </list-item>
          <list-item>
            <p>Neuroretinitis develops in approximately 1% to 2% of patients affected by cat scratch disease.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28457.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Cystoid macular edema, neovascularization of the retina or optic disc, disc swelling, epiretinal membranes, and retinal detachment are all potential causes of visual changes associated with posterior uveitis. Permanent changes encompass macular ischemia, optic nerve atrophy, and retinal scarring. Pathogens can enter the eye through bloodstream dissemination or direct introduction, possibly stemming from reactivated or new infections.</p>
        <p>Interleukins (IL) and cytokines play a significant role in the pathogenesis and persistence of intraocular inflammation. The eye is an immune-privileged site with various mechanisms to maintain this privilege. The blood-retina barrier and lack of efferent lymphatics prevent free entry and exit from the eye. Suppression of immunocompetent cells occurs through the presence of immunosuppressive factors such as transforming growth factor-beta (TGF-&#x003b2;), alpha-melanocyte&#x02013;stimulating hormone, and vasoactive intestinal peptide. Finally, the pigmented epithelia of the retina and residential retinal cells inhibit T cells and induce them to become T-regulatory cells by expressing inhibitory cell surface-associated proteins such as TGF-&#x003b2;, FAS/FAS ligand, CD46, and CD59.&#x000a0;</p>
        <p>The immunosuppressive factors typically maintain control over autoreactive T cells. However, prolonged and intense inflammation can surpass these barriers, and complex genetic&#x02013;environmental interactions break immune tolerance to generate eye-specific autoreactive T cells. Consequently, autoreactive T cells proliferate and migrate toward the eye. The failure of IL-10 and TGF-&#x003b2; to revert these cells to T-regulatory cells leads to the recruitment of neutrophils and other leukocytes due to IL-17 secretion. Tissue damage occurs due to nonspecific macrophage activation and subsequent cytokine cascades. Some evidence indicates that locally produced cytokines contribute to infectious uveitis, whereas cytokines in non-infectious uveitis appear to originate from both the eye and the peripheral blood.</p>
        <p>Cell-mediated immunity may play a significant role in viral uveitis when uveal and corneal tissue cells contain viral-specific antigens on their surface, leading to specific tissue damage such as acute retinal necrosis and CMV retinitis. CMV likely reaches the eye via hematogenous spread. Replication goes unchecked due to impaired CD4 cell function or number. Retinitis induced by CMV, VZV, HSV, and EBV can result in full-thickness retinal necrosis and edema, eventually replaced by atrophic scar tissue. This scar tissue is prone to tearing, leading to retinal detachment. Various immune regulatory cytokines&#x000a0;such as IL-6, IL-10, and interferon-gamma (IFN-&#x003b3;) are present in ocular fluid samples from patients with viral uveitis. Researchers note IL-2, IL-4, IL-6, IL-10, and&#x000a0;IFN-&#x003b3; in samples from patients with HSV-associated acute retinal necrosis.&#x000a0;</p>
        <p>Fungal uveitis, especially&#x000a0;<italic toggle="yes">Candida albicans</italic>,<italic toggle="yes">&#x000a0;</italic>stimulates interphotoreceptor retinoid-binding protein-mediated Card 9, a subgroup C-type lectin receptor (CLR1) signaling molecule, further activating Dectin-1 and Dectin-2. Both these receptors activate downstream signaling cascades, leading to helper T-cell differentiation into a Th17 phenotype and the secretion of IL-17.&#x000a0;</p>
        <p>Beh&#x000e7;et syndrome is an autoimmune inflammatory vasculitis involving arteries and veins of all sizes. The underlying pathogenesis is multifaceted, involving autoimmune and autoinflammatory features. Altered host bacteria or response to bacteria may play a role in the pathogenesis of Beh&#x000e7;et syndrome. Additional potential triggering agents may be viral illnesses or environmental factors such as chemicals and heavy metals. Molecular mimicry due to cross-reactivity of some bacterial antigens with human peptides, altered innate immune function, humoral immune activation, endothelial dysfunction, and activation of polymorphonuclear leukocytes due to increased local expression of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-&#x003b1;) and IL-1&#x003b2;, play a role in Beh&#x000e7;et syndrome.<xref ref-type="bibr" rid="article-28457.r17">[17]</xref><xref ref-type="bibr" rid="article-28457.r18">[18]</xref></p>
        <p>Patients with Beh&#x000e7;et disease<bold>&#x000a0;</bold>and uveitis have higher levels of IFN-&#x003b3;, TNF-&#x003b1;, IL-2, IL-6, IL-8, IL-12, and IL-17A in the aqueous humor. Levels of IL-15 are also significantly higher in patients with Beh&#x000e7;et disease and uveitis. IL-15 promotes the development, activation, homing, and survival of&#x000a0;natural&#x000a0;and CD8+ T cells.</p>
        <p><italic toggle="yes">T gondii</italic>&#x000a0;likely reaches the eye through hematogenous spread. Once in the eye, the parasite triggers inflammation, followed by retinitis. The choroid becomes involved secondarily. Host immune responses induce the conversion of tachyzoites to bradyzoites and their encystment, followed by scar formation. The encysted parasite may remain inactive for a prolonged period. When the cyst ruptures, the retinitis may reactivate at the border of old scars, occasionally leading to the formation of new lesions at distant locations from old scars.<xref ref-type="bibr" rid="article-28457.r1">[1]</xref></p>
        <p>Researchers suggest the role of T-cell&#x02013;mediated pathogenesis with birdshot chorioretinitis, specifically through the Th17 system. Elevated levels of IL-1&#x003b2;, IL-2, IL-6, IL-17, and TNF-&#x003b1; in the aqueous humor and increased serum levels of IL-21, IL-23, and TGF-&#x003b2;1 in patients with active disease suggest Th17-cell&#x02013;mediated inflammation.<xref ref-type="bibr" rid="article-28457.r19">[19]</xref><xref ref-type="bibr" rid="article-28457.r20">[20]</xref></p>
        <p>Elevated levels of TNF-&#x003b1;, IFN-&#x003b3;, IL6, IL-8, IL-17, macrophage inflammatory protein (MIP)-1&#x003b2;, and IL-15 in the&#x000a0;aqueous humor suggest a Th1/Th17-weighted immune response associated with Vogt-Koyanagi-Harada syndrome. Basu et al<italic toggle="yes">&#x000a0;</italic>propose<italic toggle="yes">&#x000a0;</italic>that the recognition of&#x000a0;mycobacterial by macrophages and dendritic cells activates&#x000a0;the immune pathway&#x000a0;involving Th1 and Th17 cells in the pathogenesis of tuberculosis-related uveitis.</p>
      </sec>
      <sec id="article-28457.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Unlike anterior uveitis, posterior uveitis tends to be painless but can sometimes be accompanied by pain. The symptoms are generally nonspecific and include floaters and decreased visual acuity.</p>
        <p>
<bold>Cytomegalovirus</bold>
</p>
        <p>Typically, CMV retinitis is unilateral but can become bilateral if left untreated. In addition to floaters and decreased visual acuity, patients with CMV retinitis may experience scotomata or photopsia depending on the location of retinal involvement and retinal detachment. Floaters or photopsia&#x000a0;are the single most potent symptomatic&#x000a0;indicators of CMV retinitis in patients with AIDS. The presence of either of these symptoms warrants a dilated funduscopic examination.&#x000a0;</p>
        <p>CMV retinitis typically appears as yellow-white retinal lesions with indistinct margins, sometimes with a granular appearance, often located close to retinal vessels and associated with hemorrhage (see <bold>Image.&#x000a0;</bold>Cytomegalovirus Retinitis).<xref ref-type="bibr" rid="article-28457.r21">[21]</xref>&#x000a0;The clinical appearance of CMV retinitis may appear in 3 variations as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The brush-fire type appears as wedge-shaped areas of a perivascular fluffy white lesion with many scattered hemorrhages (see&#x000a0;<bold>Image.&#x000a0;</bold>Cytomegalovirus and Associated Hemorrhages).<xref ref-type="bibr" rid="article-28457.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>The granular type has a more granular-appearing lesion with few associated hemorrhages, often displaying a central area of clearing, with an atrophic retina and stippled retinal pigment epithelium.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Retinal vasculitis with perivascular sheathing is an atypical manifestation with a clinical appearance similar to frosted branch angiitis.</p>
          </list-item>
        </list>
        <p>
<bold>Toxoplasmosis</bold>
</p>
        <p>In Europe and North America, most patients with ocular disease due to&#x000a0;<italic toggle="yes">T gondii&#x000a0;</italic>are asymptomatic, and clinicians note scarring&#x000a0;during&#x000a0;a routine examination. The retina and choroid are primarily affected, and the vitreous becomes affected secondarily. When symptomatic, floaters alone are generally the presenting symptom. Ophthalmologic examination reveals mild iritis, significant vitreous inflammation, and whitish retinal lesions, often referred to as a headlight in the fog appearance. Visual fields may show an absolute defect with a breakout to the periphery, especially if the retinitis lesions are within 1 disc diameter of the optic disc.<xref ref-type="bibr" rid="article-28457.r22">[22]</xref>&#x000a0;Recurrent lesions tend to occur as satellite lesions adjacent to old atrophic lesions (see&#x000a0;<bold>Image.&#x000a0;</bold>Toxoplasma Chorioretinitis). Perivasculitis may be present near the active lesion with periarteriolar collections of cells seen as distinct Kyrieleis plaques. Such plaques are also present in acute retinal necrosis, tuberculosis, sarcoidosis, Beh&#x000e7;et disease, CMV retinitis, leptospirosis, rickettsial disease, and syphilis.<xref ref-type="bibr" rid="article-28457.r3">[3]</xref><xref ref-type="bibr" rid="article-28457.r23">[23]</xref><xref ref-type="bibr" rid="article-28457.r24">[24]</xref>&#x000a0;Patients who are immunocompromised with toxoplasmosis may reveal less profound vitritis with multiple, atypical, or large retinitis lesions, and a pigmented scar may be absent.</p>
        <p>Punctate Outer Retinal Toxoplasmosis (PORT) is a subset of ocular toxoplasmosis involving the outer retinal layers and associated with little or no overlying vitreous reaction. Grey-white lesions in the deep retina and retinal pigment epithelium level that resolve as white, punctate tiny dots characterize PORT. Identification of this variant is important as treatment may improve overall outcomes.<xref ref-type="bibr" rid="article-28457.r25">[25]</xref></p>
        <p>
<bold>Beh&#x000e7;et Syndrome</bold>
</p>
        <p>Beh&#x000e7;et syndrome clinically manifests with recurrent oral aphthae and various systemic findings, including genital aphthae, ocular complications, skin lesions, gastrointestinal involvement, neurologic disease, vascular disease, or arthritis. Panuveitis is the predominant ocular presentation, often evolving into a chronic, relapsing course and becoming bilateral in most cases. Anterior segment inflammation commonly presents as nongranulomatous acute uveitis, with or without hypopyon. Hypopyon exhibits free movement with shifting head positions. In addition, significant media haze or vitritis may be evident.</p>
        <p>In Beh&#x000e7;et disease, retinitis is the second most common posterior segment manifestation after retinal vasculitis, exerting a greater influence on veins&#x000a0;compared to&#x000a0;arteries.<xref ref-type="bibr" rid="article-28457.r26">[26]</xref>&#x000a0;The presentation includes patchy areas of focal retinal whitening, histologically linked to retinal vasculitis, choroidal occlusive vasculitis, or primary focal retinal inflammation.<xref ref-type="bibr" rid="article-28457.r26">[26]</xref>&#x000a0;Deeper than cotton wool spots, these retinitis areas are more substantial in the posterior pole compared to the periphery, occasionally accompanied by hemorrhage, and typically resolve within 1 to 2 weeks of commencing immunosuppressive therapy.&#x000a0;Retinal atrophy may follow once the exudates and hemorrhages resolve. Cystoid macular edema resulting from vascular leakage or optic disc involvement is another noteworthy discovery.&#x000a0;</p>
        <p>
<bold>Acute Retinal Necrosis</bold>
</p>
        <p>Caused by HSV and VZV in immunocompetent hosts and CMV in immunocompromised hosts, patients with acute retinal necrosis may present with a red eye and pain in addition to the characteristic findings associated with retinitis. Patchy white-yellow areas that become confluent over time characterize acute retinal necrosis. The disease starts in the periphery with full-thickness discrete necrotizing lesions with scalloped borders. Typically, hemorrhages are less prominent if present. The posterior pole is involved later in the course of the disease. Inflammation of the arterioles can lead to occlusive arteritis, causing more rapid retinal necrosis. Other associated features include vitreal haze, optic disc edema, raised intraocular pressure, and scleritis (see <bold>Image.&#x000a0;</bold>Acute Retinal Necrosis).&#x000a0;Although the disease starts unilaterally in the majority, fellow eye involvement may occur as early as 1 to 6 weeks.<xref ref-type="bibr" rid="article-28457.r27">[27]</xref></p>
        <p>Neonatal ocular HSV may initially appear asymptomatic. Early signs include excessive watering of the eye, crying from apparent eye pain, and conjunctival erythema.</p>
        <p>PORN, an extreme variant of necrotizing herpetic retinopathy in immunocompromised individuals, presents with early involvement of the posterior pole and rapid progression. Despite extensive retinal involvement, particularly in the deep retina, minimal vitreous inflammation is present.<xref ref-type="bibr" rid="article-28457.r28">[28]</xref>&#x000a0;In a large case series by Engstrom et al, two-thirds of eyes with the disease progressed to no light perception within 4 weeks of onset.<xref ref-type="bibr" rid="article-28457.r29">[29]</xref>&#x000a0;Features similar to PORN may also be noted in immunocompetent individuals.<xref ref-type="bibr" rid="article-28457.r30">[30]</xref>&#x000a0;The whitish retina around the fovea due to retinitis may give rise to a cherry red spot at the macula.<xref ref-type="bibr" rid="article-28457.r31">[31]</xref>&#x000a0;</p>
        <p>
<bold>Cat Scratch Disease</bold>
</p>
        <p>Ocular manifestations of cat scratch disease include Parinaud's oculoglandular syndrome, neuroretinitis, papillitis, optic neuritis, and focal retinochoroiditis. Parinaud's oculoglandular syndrome manifests as regional lymphadenopathy and infection of the conjunctiva, eyelid, or adjacent skin surface due to a cat bite or lick near the eye.</p>
        <p>Patients with neuroretinitis may present with fever, malaise, and unilateral blurred vision. An afferent pupillary defect is a common finding in physical examinations. Retinal examination reveals hemorrhages, cotton wool spots, and multiple discrete lesions in the deep retina. Some individuals may develop a macular star or a stellate-appearing lesion due to leakage from the optic nerve head. Discrete white retinal and chorioretinal lesions may be a more common finding than the classic macular star. Other posterior segment findings include intermediate uveitis, granulomas, choroiditis, angiomatosis lesions, and serous retinal detachments.<xref ref-type="bibr" rid="article-28457.r32">[32]</xref></p>
        <p>
<bold>Syphilis</bold>
</p>
        <p>In the ocular context, secondary syphilis can lead to either granulomatous or nongranulomatous anterior uveitis, episcleritis, scleritis, chorioretinitis, vitritis, retinal vasculitis, or papillitis. The later stages of secondary syphilis often affect the posterior segment of the eye. Tertiary syphilis may induce gummas of the eyelid, anterior and posterior uveitis, retinal vasculitis, keratitis, scleritis, or papillitis. In addition, tertiary syphilis can manifest as an Argyll Robertson pupil, characterized by bilaterally small pupils with minimal response to light but normal response to near stimuli.</p>
        <p>The typical posterior appearance of syphilis is a large, roundish, yellowish placoid lesion known as acute posterior placoid chorioretinopathy occurring at the level of the retinal pigment epithelium at the macular or paramacular area.<xref ref-type="bibr" rid="article-28457.r6">[6]</xref>&#x000a0;An additional hallmark of ocular syphilis is pre-retinal lesions appearing as dots overlying retinitis, resulting in punctuate retinitis. However, syphilis can cause multiple other lesions, including necrotizing chorioretinitis, exudative retinal detachment, retinal vasculitis, papillitis, and neuroretinitis.</p>
        <p>
<bold>Tuberculosis</bold>
</p>
        <p>Clinically, tubercular lesions involve the choroid more than the retina. The features include a small choroidal tubercle appearing as a yellowish choroidal nodule, a large elevated choroidal granuloma or choroidal tuberculoma, and a choroidal or subretinal abscess. Tubercular infection is likely related to serpiginous-like choroiditis. There are two forms of serpiginous choroiditis. The first is a placoid form with a yellowish lesion that occupies the posterior pole. Another presentation is a multifocal serpiginous form characterized by multiple yellow-whitish lesions in the posterior pole and mid-periphery corresponding with areas of choriocapillaritis.<xref ref-type="bibr" rid="article-28457.r33">[33]</xref><xref ref-type="bibr" rid="article-28457.r34">[34]</xref><xref ref-type="bibr" rid="article-28457.r35">[35]</xref></p>
        <p>
<bold>Rocky Mountain Spotted Fever</bold>
</p>
        <p>Patients with RMSF may also present with eye pain and the characteristic features associated with retinitis. Ocular manifestations of RMSF include conjunctivitis, keratitis, anterior uveitis, panuveitis, retinitis, retinal vascular changes, and optic nerve involvement. RMSF presents as white retinal lesions, typically adjacent to retinal vessels, disc swelling, and macular subretinal fluid with mild to moderate vitreous inflammation.&#x000a0;</p>
        <p>
<bold>Toxocariasis</bold>
</p>
        <p>The most common presenting features of ocular toxocariasis are strabismus and decreased visual acuity. Toxocara retinochoroiditis may manifest acutely as a blurred, indistinct white lesion accompanied by overlying vitritis. After inflammation resolution, the lesion appears as a well-defined, elevated white mass, ranging from&#x000a0;0.5 to 4 disc diameters in size, with associated vitreoretinal traction. However, the prevalent ocular characteristic is a granuloma in the posterior pole, observed in 25% to 50% of patients.<xref ref-type="bibr" rid="article-28457.r36">[36]</xref></p>
        <p>
<bold>Chikungunya Fever</bold>
</p>
        <p>Chikungunya virus presents as an acute febrile polyarthralgia and inflammatory arthritis, in addition to acute cutaneous eruptions and headache, conjunctivitis, and gastrointestinal symptoms. The associated retinitis may morphologically mimic herpetic retinitis, but the chikungunya virus presents with markedly less vitreous reaction and confluent posterior pole retinitis. The absence of a history of fever, joint pains, and skin rash before the onset of visual symptoms can also differentiate chikungunya from acute retinal necrosis.<xref ref-type="bibr" rid="article-28457.r37">[37]</xref>&#x000a0;Posterior uveitis can present with no involvement of the anterior segment. Other posterior segment signs include optic neuritis, neuroretinitis, and retrobulbar neuritis.</p>
        <p>
<bold>Endogenous Endophthalmitis</bold>
</p>
        <p>Endogenous endophthalmitis may present with signs of severe endophthalmitis, including fibrin in the anterior chamber, hypopyon, and severe vitritis obscuring the view of the retina.<xref ref-type="bibr" rid="article-28457.r38">[38]</xref>&#x000a0;Early cases of fungal endogenous endophthalmitis may present as creamy white or yellow chorioretinal lesions, typically at the posterior pole at or near the fovea, associated with fluffy vitreous opacities. These lesions may form a string of pearls appearance.<xref ref-type="bibr" rid="article-28457.r39">[39]</xref>&#x000a0;Advanced cases of endogenous endophthalmitis may present as a subretinal abscess.<xref ref-type="bibr" rid="article-28457.r40">[40]</xref></p>
        <p>
<bold>Diffuse Unilateral Subacute Neuroretinitis</bold>
</p>
        <p>Patients with&#x000a0;diffuse unilateral subacute neuroretinitis present with multifocal gray-white evanescent lesions at the level of the outer retina, typically clustered in 1 segment of the fundus. These evanescent lesions are believed to result from the host's immune response to the nematode in the subretinal space and characteristically migrate depending on the worm's location. In the later stages of the disease, there may be sequelae of degenerative changes in the retinal pigment epithelium and retina, retinal artery narrowing, and optic atrophy.&#x000a0;</p>
        <p>
<bold>West Nile Virus</bold>
</p>
        <p>West Nile virus typically manifests as clusters of creamy yellow, deep chorioretinal lesions and scars arranged in a line.<xref ref-type="bibr" rid="article-28457.r41">[41]</xref>&#x000a0;</p>
        <p>Post-fever retinitis presents as&#x000a0;multiple white retinal lesions and macular edema (see&#x000a0;<bold>Image.&#x000a0;</bold>Post-Fever Retinitis).</p>
        <p>
<bold>Dengue Fever</bold>
</p>
        <p>Dengue fever can cause retinal vasculitis, yellow subretinal lesions, and foveolitis, or a round yellowish lesion at the fovea.<xref ref-type="bibr" rid="article-28457.r41">[41]</xref>&#x000a0;Cerebriform retinitis has been reported in association with parotid swelling.<xref ref-type="bibr" rid="article-28457.r42">[42]</xref>&#x000a0;</p>
        <p>
<bold>Sarcoidosis</bold>
</p>
        <p>Sarcoid uveitis-related chorioretinitis commonly presents as multiple small round lesions in the inferior peripheral fundus, which heal with either hyperpigmentation or hypopigmentation. A characteristic manifestation of ocular sarcoidosis is the presence of optic disc granuloma accompanied by multiple arteriolar macroaneurysms.<xref ref-type="bibr" rid="article-28457.r43">[43]</xref></p>
        <p>
<bold>Subacute Sclerosing Panencephalitis</bold>
</p>
        <p>The clinical symptoms of&#x000a0;subacute sclerosing panencephalitis begin with neurologic symptoms such as personality changes, lethargy, difficulty in school, and unusual behavior lasting from weeks to years. Myoclonus, worsening dementia, and long-tract motor or sensory disease follow, lasting 3 to 12 months. Finally, further neurologic deterioration with eventual flaccidity or decorticate rigidity and symptoms and signs of autonomic dysfunction followed by a vegetative state and death occur.&#x000a0;</p>
        <p>Visual symptoms may also precede neurological symptoms. The classic lesion is a focal necrotizing macular retinitis forming a chorioretinal scar with pigmentation in healed lesions. Unlike retinitis associated with toxoplasmosis, vitritis is not a feature. Retinal hemorrhages, edema, and retinal detachment may also occur.<xref ref-type="bibr" rid="article-28457.r44">[44]</xref>&#x000a0;Vision loss may be due to chorioretinitis, cortical blindness, or optic disc changes, including papillitis, papilledema, and optic atrophy (see <bold>Image.&#x000a0;</bold>Subacute Sclerosing Panencephalitis).</p>
      </sec>
      <sec id="article-28457.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The primary evaluation of retinitis begins with a thorough ophthalmologic examination, including funduscopic photos.<xref ref-type="bibr" rid="article-28457.r45">[45]</xref>&#x000a0;Slit-lamp examination is essential in the evaluation of posterior uveitis. Other potential ocular testing involves the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluorescein fundus angiography (FFA)</p>
          </list-item>
          <list-item>
            <p>Optical coherence tomography (OCT)</p>
          </list-item>
          <list-item>
            <p>Ultrasound: To exclude retinal detachment and assess the severity of vitreous inflammation when the media is very hazy</p>
          </list-item>
          <list-item>
            <p>Bacterial, fungal, and viral culture and sensitivity and staining tests, including KOH and gram staining, of the aqueous or vitreous&#x000a0;humor</p>
          </list-item>
          <list-item>
            <p>Polymerase chain reaction (PCR) for bacteria, fungi,&#x000a0;<italic toggle="yes">Toxoplasma</italic>, HSV, HZV, and CMV of the aqueous and vitreous humor depending on the clinical presentation</p>
          </list-item>
          <list-item>
            <p>Retinal or chorioretinal biopsy or fine-needle aspiration&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Visual field assessment&#x000a0;</p>
          </list-item>
        </list>
        <p>Patients presenting with posterior uveitis and no evidence of an underlying etiology should undergo a chest radiograph to evaluate for pulmonary sarcoidosis or infections such as tuberculosis. In addition, affected patients should undergo serology for clinically silent syphilis.</p>
        <p>
<bold>Cytomegalovirus</bold>
</p>
        <p>The diagnosis of CMV retinitis is clinical. A thorough funduscopic examination is crucial to differentiate CMV retinitis from benign cotton wool spots and PORN. The key differentiating features&#x000a0;include&#x000a0;the initial presentation of PORN with multifocal, necrotizing lesions in the peripheral retina, which progresses more rapidly than CMV retinitis. Unlike CMV retinitis, PORN typically spares the retinal vessels. CMV serology is not helpful in the diagnosis of CMV retinitis. Patients with CMV retinitis should also undergo testing for HIV and may require a CD4 count.</p>
        <p>
<bold>Toxoplasmosis</bold>
</p>
        <p>Clinicians diagnose ocular toxoplasmosis based on clinical presentation and detection of anti-<italic toggle="yes">Toxoplasma</italic>&#x000a0;immunoglobulin G (IgG) antibodies. Testing involves enzyme-linked immunosorbent assay (ELISA) for IgM and IgG antibodies. Although acute infections exhibit IgG antibodies, IgM may no longer be detectable since ocular involvement can occur months later. A positive IgG supports but does not confirm diagnosis, especially in immunocompromised patients. Additional tests include aqueous humor sampling for local antibody production, PCR testing for&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;DNA, and, rarely, vitreal cytopathology. Neuroimaging is crucial to exclude central nervous system involvement in immunocompromised patients. OCT reveals abnormal hyperreflectivity in retinal layers at infection sites, whereas FFA shows early blockage followed by lesion leakage.<xref ref-type="bibr" rid="article-28457.r46">[46]</xref>&#x000a0;</p>
        <p>
<bold>Herpes Simplex Virus</bold>
</p>
        <p>Neonates and infants up to 6 weeks with evidence of skin, eye, and mouth disease should undergo a thorough evaluation for CNS and disseminated disease. Clinicians can establish the diagnosis of neonatal HSV infection by isolating HSV in culture, detecting HSV DNA using qualitative or quantitative PCR, or detecting HSV antigens using direct immunofluorescence assays (DFA). Neonates with suspected HSV infection should undergo the following tests:</p>
        <list list-type="bullet">
          <list-item>
            <p>Viral culture or HSV PCR on surface swabs of the conjunctivae, mouth, nasopharynx, and rectum</p>
          </list-item>
          <list-item>
            <p>Viral culture or HSV PCR (with or without DFA) of swabs or scrapings of any skin and mucous membrane lesions</p>
          </list-item>
          <list-item>
            <p>Cerebrospinal fluid HSV PCR</p>
          </list-item>
          <list-item>
            <p>Whole blood or plasma HSV PCR</p>
          </list-item>
          <list-item>
            <p>Viral culture or HSV PCR of tracheal aspirate if intubated</p>
          </list-item>
        </list>
        <p>Neonates who have confirmed HSV infection should also undergo additional testing to determine the extent of the infection as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count, including differential and platelet count</p>
          </list-item>
          <list-item>
            <p>Serum transaminases&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Total and direct bilirubin</p>
          </list-item>
          <list-item>
            <p>Blood urea nitrogen and creatinine</p>
          </list-item>
          <list-item>
            <p>Urinalysis</p>
          </list-item>
          <list-item>
            <p>Lumbar puncture, if not already completed</p>
          </list-item>
          <list-item>
            <p>Ophthalmologic examination</p>
          </list-item>
          <list-item>
            <p>Neuroimaging</p>
          </list-item>
          <list-item>
            <p>Electroencephalogram (EEG) in the presence of additional central nervous system involvement, such as seizures or an abnormal neurological examination</p>
          </list-item>
          <list-item>
            <p>Chest radiograph in the presence of pulmonary findings</p>
          </list-item>
        </list>
        <p>
<bold>Acute retinal necrosis</bold>
</p>
        <p>The American Uveitis Society defines acute retinal necrosis based on the following clinical characteristics.</p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of 1 or more foci of retinal necrosis with discrete borders located in the peripheral retina.</p>
          </list-item>
          <list-item>
            <p>A rapid progression of the disease in the absence of antiviral therapy.</p>
          </list-item>
          <list-item>
            <p>Circumferential spread.</p>
          </list-item>
          <list-item>
            <p>Evidence of occlusive vasculopathy with arterial involvement.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A prominent inflammatory reaction in the vitreous and anterior chamber.<xref ref-type="bibr" rid="article-28457.r47">[47]</xref></p>
          </list-item>
        </list>
        <p>In cases with an unclear underlying etiology, clinicians should perform PCR testing of the vitreous and aqueous humor for VZV, HSV, CMV, EBV, and toxoplasmosis. In addition, fourth-generation antigen/antibody combination HIV-1/2 immunoassay plus a confirmatory HIV-1/HIV-2 antibody differentiation immunoassay, fluorescent treponemal antibody absorption (FTA-ABS) and rapid plasma reagin (RPR) for syphilis, erythrocyte sedimentation rate (ESR), toxoplasmosis IgG and IgM, purified protein derivative (PPD) skin test, and chest radiograph can help in evaluating for other potential etiologies. OCT reveals fragmentation of retinal tissue.<xref ref-type="bibr" rid="article-28457.r30">[30]</xref> Treatment should not be withheld while awaiting results.</p>
        <p>
<bold>Beh&#x000e7;et Disease</bold>
</p>
        <p>For ocular Beh&#x000e7;et disease, FFA is the gold standard in evaluating the activity and extent of retinal vasculitis. FFA reveals retinal infiltrates, retinal nerve fiber layer defects, occlusive retinal vasculitis, and a fern-like leakage pattern due to diffuse retinal capillary leakage in the mid-phase of the angiogram.<xref ref-type="bibr" rid="article-28457.r48">[48]</xref>&#x000a0;Vessel wall staining and leakage suggest increased vascular permeability caused by the breakdown of the inner blood-retinal barrier. FFA also aids in monitoring response to treatment. OCT and optical coherence tomography angiography (OCTA) help reveal disease activity not otherwise identified and may be beneficial in identifying and monitoring early disease activity.</p>
        <p>
<bold>Rocky Mountain Spotted Fever</bold>
</p>
        <p>Along with the clinical findings, clinicians confirm the diagnosis of RMSF using indirect immunofluorescence assay tests. Initial high antibody titer or a four-fold rise in the convalescent serum titer indicates a positive result. Case confirmation with serology might take 2 to 3 weeks. Serological testing using western blot or detecting rickettsiae in blood or tissue using PCR may be necessary in selected cases.</p>
        <p>
<bold>Syphilis</bold>
</p>
        <p>Clinicians use both treponemal tests, such as the FTA-ABS, and nontreponemal tests, such as the RPR and Venereal Disease Research Laboratory (VDRL), to diagnose syphilis. Screening may start with&#x000a0;one and&#x000a0;then confirmation of a positive result is necessary with the other. Some labs do have PCR available to detect&#x000a0;<italic toggle="yes">T pallidum</italic>&#x000a0;DNA. Patients with suspected neurosyphilis require cerebrospinal fluid-VDRL.&#x000a0;</p>
        <p>
<bold>Lyme Disease</bold>
</p>
        <p>Patients&#x000a0;presenting with erythema migrans recently traveling to an endemic area do not require further testing. For the remainder of patients, clinicians base the diagnosis on clinical findings and serological data such as an ELISA test for IgM and IgG, which peak during the first month, followed by a western blot test.</p>
        <p>
<bold>Subacute Sclerosing Panencephalitis</bold>
</p>
        <p>Elevated serum anti-measles antibody concentration and cerebrospinal fluid&#x000a0;revealing elevated protein concentration and detectable anti-measles antibody characterize subacute sclerosing panencephalitis.&#x000a0;Pathognomonic EEG changes during stage II demonstrate bursts of high-voltage complexes of 2 to 3 per second delta waves and sharp waves, followed by a relatively flat pattern. Computed tomography (CT) of the brain may reveal atrophy and scarring.&#x000a0;</p>
        <p>
<bold>Tuberculosis</bold>
</p>
        <p>Ocular tuberculosis can be primary or secondary. If secondary, the patient may have active or latent disease. Patients with active disease will show active lesions on chest radiographs, and a sputum sample stained for acid-fast bacilli may confirm the diagnosis. In contrast, patients with latent tuberculosis have a normal chest radiograph but a positive tuberculin skin test or interferon-gamma release assay (IGRA). Diagnosing ocular tuberculosis is challenging as fluid from the eye is typically negative for tuberculosis on both culture and PCR. Directly performing&#x000a0;IGRA on fluid from the eye appears to be a promising technique.</p>
        <p>
<bold>Dengue Fever</bold>
</p>
        <p>FFA reveals nonischemic venular occlusion. OCT helps evaluate and monitor the extent of macular edema. Clinicians perform PCR to detect viral genomes during the first week of illness, followed by testing for virus-specific IgM and IgG.</p>
        <p>
<bold>Sarcoidosis</bold>
</p>
        <p>The diagnosis of sarcoidosis begins with a thorough physical examination and appropriate testing to exclude other potential etiologies for the patient's symptoms. Sarcoidosis-specific testing begins with a chest radiograph followed by a high-resolution CT of the chest. Patients with mediastinal lymphadenopathy should also undergo testing for HIV and tuberculosis. Many patients require histopathologic detection of non-necrotizing granulomas unless the clinical presentation overwhelmingly supports the diagnosis.</p>
        <p>
<bold>Cat Scratch Disease</bold>
</p>
        <p>The predominant diagnostic approach is serological testing. An immunofluorescence assay IgG titer exceeding 1:64 suggests a possible&#x000a0;<italic toggle="yes">B henselae</italic>&#x000a0;infection, whereas a titer exceeding&#x000a0;1:256 strongly implies a recent or acute infection. PCR testing of ocular fluid&#x000a0;is used&#x000a0;to confirm the diagnosis.</p>
      </sec>
      <sec id="article-28457.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Topical medications exhibit limited effectiveness against posterior uveitis. Periodically, clinicians use difluprednate, a topical corticosteroid with better vitreous humor penetration for inflammation posterior to the lens. Alternatives involve vigilant monitoring, along with periocular or intraocular glucocorticoid injections. Systemic glucocorticoids are considered for severe or bilateral disease, or in individuals with glaucoma when local injections are impractical. Conditions such as Beh&#x000e7;et syndrome or serpiginous choroiditis may necessitate systemic treatment. Immunosuppressive agents become essential for cases with bilateral involvement, persistent inflammation, oral glucocorticoid resistance, or severe impairment of daily activities. Patients requiring 10 mg or more of daily prednisone may benefit from steroid-sparing agents such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, or tacrolimus. TNF inhibitors are cautiously reserved, primarily for severe Beh&#x000e7;et syndrome, due to their potential adverse effects.</p>
        <p>Injected or surgically implanted intraocular fluocinolone, a long-acting glucocorticoid, is a treatment option for patients with non-infectious posterior uveitis requiring frequent intraocular injections. Surgically implanted formulations release medication continuously for approximately 2.5 years. At the onset of Vogt-Koyanagi-Harada disease, patients may need intravenous methylprednisolone. Regardless of the therapeutic option chosen, patients must have continued ophthalmologic examinations to monitor treatment response and determine treatment length.</p>
        <p>
<bold>Beh&#x000e7;et Syndrome</bold>
</p>
        <p>Treatment for Beh&#x000e7;et syndrome aims to control the inflammation, reduce the frequency of recurrences, and avoid complications. Corticosteroids and immunomodulatory therapy are the mainstays of treatment. Topical corticosteroids and cycloplegic agents such as scopolamine or cyclopentolate are the primary treatments for anterior uveitis. If the inflammation continues, systemic glucocorticoids&#x000a0;such as&#x000a0;prednisone 40mg/d, weaned over 1 month, are appropriate.</p>
        <p>Variations in opinions exist regarding initial treatment for posterior uveitis associated with Bechet syndrome. Clinicians utilize systemic glucocorticoids, azathioprine, cyclosporine, IFN-&#x003b1;, or a monoclonal TNF-&#x003b1; antagonist. In many instances, the preferred combination is systemic glucocorticoids plus azathioprine. In the presence of an initial or recurrent episode of severe sight-threatening disease, systemic glucocorticoids plus a monoclonal TNF-&#x003b1; inhibitor such as infliximab is preferred.<xref ref-type="bibr" rid="article-28457.r49">[49]</xref><xref ref-type="bibr" rid="article-28457.r50">[50]</xref>&#x000a0;An expert panel from the American Uveitis Society recommends initial treatment with TNF-&#x003b1; inhibitors due to the observed improvement in ocular manifestations compared to other treatments.</p>
        <p>In all cases of infective retinitis, the antimicrobial should be initiated first, followed by steroids.&#x000a0;Initiating steroids in the presence of infective retinitis or panuveitis without antimicrobial coverage may result in severe ocular damage and could be life-threatening if systemic disease is present.</p>
        <p>
<bold>CMV Retinitis</bold>
</p>
        <p>Current treatments for CMV retinitis include intravenous and intravitreal ganciclovir and foscarnet, intravenous cidofovir, and oral valganciclovir. Adequate treatment of the underlying immunocompromising condition is essential. Treatment regimens depend on the location of the lesions. Oral valganciclovir, a ganciclovir prodrug with enhanced bioavailability, is first-line therapy for CMV retinitis. Intravenous ganciclovir is appropriate for patients who are unable to tolerate oral medications and involves induction therapy at 5 mg/kg every 12 hours for 14 to 21 days, followed by a maintenance dose of 5 mg/kg/d. Valganciclovir induction therapy consists of 900 mg twice daily, followed by 900 mg/d for maintenance.<xref ref-type="bibr" rid="article-28457.r51">[51]</xref><xref ref-type="bibr" rid="article-28457.r52">[52]</xref>&#x000a0;The primary adverse reaction is myelosuppression, necessitating regular blood count monitoring.</p>
        <p>Immediate sight-threatening lesions, those close to the macula or head of the optic nerve, warrant local intravitreal injections and systemic therapy. The remaining patients can use systemic therapy alone. Induction therapy continues for 2 to 3 weeks until the retinitis is inactive, and then the dose is lowered to a maintenance dose. Because ganciclovir is not virucidal, the United States Centers for Disease Control (CDC) guidelines recommend chronic maintenance therapy be continued for AIDS-related CMV retinitis until patients maintain an increase in the CD4+ lymphocyte count greater than 100 to 150 cells/&#x000b5;L for 6 months or longer.<xref ref-type="bibr" rid="article-28457.r53">[53]</xref></p>
        <p>Patients with immediate sight-threatening lesions receive local therapy with an intravitreal injection of ganciclovir 2.5 mg/0.05 mL weekly for 2 to 3 weeks or foscarnet 2.4 mg/injection administered twice weekly for 2 to 4 doses with concurrent systemic therapy.<xref ref-type="bibr" rid="article-28457.r54">[54]</xref>&#x000a0;Clinicians can discontinue intravitreal injections once the retinal opacity resolves. If systemic therapy begins within 24 hours of intravitreal injections, subsequent injections may be unnecessary.</p>
        <p>Clinicians can also surgically implant intravitreal ganciclovir implants containing a minimum of 4.5 mg of ganciclovir through the pars plana. These implants&#x000a0;act for 6 to 8 months and have a low-risk profile; however, they do not afford any protection for the contralateral eye or other visceral involvement. Immune recovery uveitis is another potential finding after beginning antiretroviral therapy in patients with AIDS with CMV retinitis. Affected patients present with anterior segment inflammation, posterior synechia, cataract, vitritis, cystoid macular edema, and epiretinal membrane.&#x000a0;</p>
        <p>
<bold>Toxoplasmosis</bold>
</p>
        <p>Immunocompetent patients with&#x000a0;<italic toggle="yes">Toxoplasma</italic>-related chorioretinitis usually experience a self-limited infection that resolves spontaneously in 4 to 8 weeks. However, treatment is warranted for the following groups of patients.</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunocompromised patients</p>
          </list-item>
          <list-item>
            <p>Pregnant women with acquired disease</p>
          </list-item>
          <list-item>
            <p>Patients with multiple active lesions</p>
          </list-item>
          <list-item>
            <p>Patients with lesions within the vascular arcades or adjacent to the optic disk or fovea</p>
          </list-item>
          <list-item>
            <p>Lesions larger than 1 optic disk diameter</p>
          </list-item>
          <list-item>
            <p>When visual acuity drops below 20/40 in a previously 20/20 eye</p>
          </list-item>
          <list-item>
            <p>The patient has sustained a 2-line drop in vision</p>
          </list-item>
        </list>
        <p>Trimethoprim-sulfamethoxazole (TMP-SMX) 160 mg TMP/800 mg SMX twice daily in patients with normal renal function for 6 weeks is a first-line therapy in nonpregnant individuals. Traditionally, pyrimethamine combined with sulfadiazine has been the treatment of choice, and both regimens have comparable efficacy. However, TMP-SMX is associated with fewer adverse effects and is more cost-effective, with higher availability in some countries.<xref ref-type="bibr" rid="article-28457.r55">[55]</xref><xref ref-type="bibr" rid="article-28457.r56">[56]</xref><xref ref-type="bibr" rid="article-28457.r57">[57]</xref>&#x000a0;An additional alternative is pyrimethamine, sulfadiazine, and leucovorin. Patients who are intolerant to systemic therapy can receive intravitreal clindamycin 1.0 mg/0.1 mL with 1 or more injections administered over 6 weeks. Clinicians determine the number of injections based on the disease activity at the time of diagnosis.</p>
        <p>Patients with significant vitreous inflammation and retinal vasculitis should receive glucocorticoids in addition to antimicrobial therapy. Clinicians initiate steroids 2 to 3 days after the initiation of antimicrobial therapy. The typical starting dose is prednisone 40 mg or 0.5mg/kg/d for a week, followed by a gradual taper. The goal is to have the dose &#x0003c;10 mg/d on discontinuing systemic antibiotics. Patients who receive intravitreal clindamycin may also receive intravitreal dexamethasone 0.4 mg/0.1 mL.&#x000a0;</p>
        <p>
<bold>Toxocariasis</bold>
</p>
        <p>Management options for ocular larva migrans include systemic and topical steroids, anthelmintic&#x000a0;drugs, and pars plana vitrectomy. For sight-threatening ocular inflammation, patients should receive prednisone 0.5 to 1 mg/kg/d followed by a slow taper. The benefits of adding an anthelmintic are unclear, but adding albendazole 400 mg twice daily for 2 weeks with a fatty meal reduces recurrences. Albendazole is preferred over mebendazole in CNS or ocular involvement because albendazole crosses the blood-brain barrier.</p>
        <p>
<bold>Syphilis</bold>
</p>
        <p>Clinicians manage ocular syphilis similarly to neurosyphilis, utilizing penicillin as the preferred treatment. Acceptable regimens are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Aqueous crystalline penicillin G at a dosage of 18 to 24 million units per day, administered as 3 to 4 million&#x000a0;units intravenous every 4 hours, or 18 to 24 million units per day daily as a continuous infusion for 10 to 14 days; or</p>
          </list-item>
          <list-item>
            <p>Procaine penicillin G at a dosage of 2.4 million units intramuscular once daily plus probenecid 500 mg orally 4 times a day, both for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>Clinicians often add oral or topical glucocorticoids. Ceftriaxone or doxycycline are alternatives for patients who are allergic to penicillin.&#x000a0;</p>
        <p>
<bold>Tuberculosis</bold>
</p>
        <p>The treatment for ocular tuberculosis follows the same approach as pulmonary tuberculosis. Patients with paramacular and optic nerve head tuberculosis also receive systemic glucocorticoids.<xref ref-type="bibr" rid="article-28457.r58">[58]</xref><xref ref-type="bibr" rid="article-28457.r59">[59]</xref>&#x000a0;Patients who develop neovascularization may require photocoagulation of the retina.&#x000a0;</p>
        <p>
<bold>Acute Retinal Necrosis</bold>
</p>
        <p>The treatment of acute retinal necrosis should be initiated early to hasten the resolution of the disease in the infected eye and prevent contralateral disease. Initially, patients should be hospitalized and treated with a 10- to 14-day course of intravenous acyclovir 10 to 15 mg/kg every 8 hours, followed by oral acyclovir 800 mg 5&#x000a0;times a day for 6 to 12 weeks.<xref ref-type="bibr" rid="article-28457.r60">[60]</xref>&#x000a0;Recently, outpatient treatment with orally administered valacyclovir 2 g 3 times&#x000a0;a day has been shown to achieve systemic levels similar to intravenous acyclovir.<xref ref-type="bibr" rid="article-28457.r61">[61]</xref><xref ref-type="bibr" rid="article-28457.r62">[62]</xref>&#x000a0;Local treatment with intravitreal injections of ganciclovir 2 mg/0.1 mL is effective in treating sight-threatening herpetic infections with fovea or optic disc involvement.</p>
        <p>Oral steroids should be administered under antiviral cover, starting 24 to 48 hours after antiviral therapy, particularly in cases with optic nerve involvement. The role of prophylactic laser posterior to the area of active retinitis in preventing retinal detachment in the setting of recent acute retinal necrosis remains unclear. Early surgery for an actual retinal detachment associated with acute retinal necrosis is crucial.<xref ref-type="bibr" rid="article-28457.r63">[63]</xref>&#x000a0;</p>
        <p>
<bold>Metastatic or Endogenous Endophthalmitis</bold>
</p>
        <p>Affected patients require urgent control of the systemic infection or focus of infection. Ocular management includes intravitreal antimicrobial therapy and vitrectomy. In such cases, The visual prognosis is usually poor.</p>
        <p>
<bold>Subacute Sclerosing Panencephalitis</bold>
</p>
        <p>No cure exists for subacute sclerosing panencephalitis. Most treatment involves symptom management. Some therapies reveal stabilization and prolongation of life, but those effects prove to be only temporary. A study reveals that a combination of intraventricular interferon-alpha treatment and isoprinosine induces remission in 44% to 55% of the cases studied. A long-term follow-up reveals that remission is only temporary. Amantadine improves survival, but isoprinosine is 4 times more effective compared to amantadine and twice as effective as interferon alpha. In addition, healthcare professionals use ribavirin and carbamazepine.</p>
        <p>
<bold>Lyme Disease</bold>
</p>
        <p>Doxycycline, ceftriaxone, and amoxicillin can treat any stage of Lyme disease, with ceftriaxone preferred for CNS involvement. These medications are also effective in treating ocular disease, with some studies suggesting that cephalosporins have better ocular penetration. Affected patients also likely require glucocorticoid therapy to control inflammation.</p>
        <p>
<bold>Dengue Fever</bold>
</p>
        <p>Most patients with ocular manifestations of dengue fever recover fully without therapeutic interventions. However, patients&#x000a0;with bilateral involvement or severe ocular symptoms may receive systemic glucocorticoids or immunoglobulins.</p>
        <p>
<bold>Cat Scratch Disease</bold>
</p>
        <p>The optimal treatment regimen for cat scratch disease is unclear. Experts recommend doxycycline and rifampin for patients aged&#x000a0;8 or older. For patients younger than 8 or unable to tolerate doxycycline, the regimen includes rifampin plus azithromycin or TMP-SMX. Clinicians administer either choice for 4 to 6 weeks. In addition, patients receive 1 mg/kg/d of oral steroids for 2 weeks, followed by a gradual 4-week taper.</p>
        <p>
<bold>Sarcoidosis</bold>
</p>
        <p>The initial management of the ocular symptoms of sarcoidosis involves systemic oral or intravenous glucocorticoids in doses of 1 to 1.5 mg/kg/d. Methotrexate and mycophenolate mofetil are often utilized early in ocular disease as steroid-sparing agents. Azathioprine and cyclosporine are additional alternatives. Clinicians may consider adalimumab and other systemic immunomodulators if other immunosuppressive medications fail.</p>
        <p>
<bold>Rocky Mountain Spotted Fever</bold>
</p>
        <p>Doxycycline or chloramphenicol are the antimicrobials of choice to treat RMSF. Corticosteroids and cycloplegics are also utilized to treat ocular symptoms.&#x000a0;</p>
      </sec>
      <sec id="article-28457.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The list of differential diagnoses is extensive, including distinguishing between the various diagnoses discussed throughout this topic. Additional diagnoses to consider in patients with&#x000a0;Beh&#x000e7;et disease are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic lupus erythematosus</p>
          </list-item>
          <list-item>
            <p>Reactive arthritis</p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease</p>
          </list-item>
          <list-item>
            <p>Celiac disease</p>
          </list-item>
          <list-item>
            <p>Stevens-Johnson syndrome</p>
          </list-item>
          <list-item>
            <p>Pemphigoid</p>
          </list-item>
          <list-item>
            <p>Pemphigus</p>
          </list-item>
          <list-item>
            <p>Lichen planus</p>
          </list-item>
          <list-item>
            <p>Linear IgA bullous dermatosis</p>
          </list-item>
          <list-item>
            <p>Medication effects, including those of methotrexate, other chemotherapy agents, and nicorandil</p>
          </list-item>
          <list-item>
            <p>Nutritional deficiencies such as vitamin B12, iron, and folic acid</p>
          </list-item>
          <list-item>
            <p>Recurrent aphthous stomatitis</p>
          </list-item>
          <list-item>
            <p>Cyclic neutropenia</p>
          </list-item>
          <list-item>
            <p>Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome</p>
          </list-item>
          <list-item>
            <p>Hyperimmunoglobulinemia D syndrome</p>
          </list-item>
          <list-item>
            <p>A20 haploinsufficiency</p>
          </list-item>
        </list>
        <p>Additional diagnoses to consider in patients with CMV include benign cotton wool spots and immune recovery uveitis.</p>
        <p>Pseudotumor cerebri can also mimic the much less frequent bilateral cat scratch disease.&#x000a0;</p>
        <p>Children with retinoblastoma and ocular toxocariasis can present with strabismus, poor vision, and leukocoria. Clinicians should consider ocular toxoplasmosis and tuberculosis when considering the diagnosis of toxocariasis.</p>
        <p>Potential causes of granulomatous uveitis are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Candida</p>
          </list-item>
          <list-item>
            <p>Histoplasmosis</p>
          </list-item>
          <list-item>
            <p>Cryptococcosis</p>
          </list-item>
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
          <list-item>
            <p>Post-streptococcal infections</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Vogt-Koyanagi-Harada disease</p>
          </list-item>
          <list-item>
            <p>Sympathetic ophthalmia</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Blau syndrome</p>
          </list-item>
          <list-item>
            <p>Histiocytosis</p>
          </list-item>
          <list-item>
            <p>Granuloma annulare</p>
          </list-item>
          <list-item>
            <p>Lens-induced uveitis</p>
          </list-item>
          <list-item>
            <p>Common variable immune deficiency</p>
          </list-item>
          <list-item>
            <p>Juvenile idiopathic arthritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28457.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Visual outcomes vary based on the infecting microbe, the patient's immune status, and specific retinal involvement sites. Generally, the prognosis is favorable with appropriate treatment. Vision loss may result from foveal or optic disc involvement, choroidal neovascularization, macular scarring, or optic atrophy. Rhegmatogenous retinal detachment due to breaks in the thin, necrotic retina can also cause visual loss. Poor prognostic factors for retinitis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Progressive outer retinal necrosis:&#x000a0;PORN tends to progress or recur, leading to a dismal prognosis. Most affected patients subsequently experience total retinal detachments and minimal-to-no light perception.<xref ref-type="bibr" rid="article-28457.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Beh&#x000e7;et syndrome:&#x000a0;If not treated, Beh&#x000e7;et syndrome<bold>&#x000a0;</bold>causes blindness.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Neonatal HSV:&#x000a0;Skin, eye, and mouth disease may appear benign at the onset of the illness but is associated with a high risk of progression to the central nervous system or disseminated disease if not treated.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute retinal necrosis:&#x000a0;Visual outcomes associated with acute retinal necrosis are generally poor, primarily due to retinal detachment, but may also be due to chronic vitritis, epiretinal membrane, macular ischemia, and optic neuropathy.<xref ref-type="bibr" rid="article-28457.r53">[53]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Subacute sclerosing panencephalitis:&#x000a0;Subacute sclerosing panencephalitis&#x000a0;is a lethal disease associated with a very poor prognosis in terms of salvage of vision.</p>
          </list-item>
          <list-item>
            <p>Cat scratch disease: Most patients with neuroretinitis have a good long-term prognosis. Patients with macular exudates may experience residual defects such as optic disk pallor, diminished contrast sensitivity, and altered color vision. Additional complications are macular holes with posterior vitreous detachment.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28457.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The complications of retinitis include blindness,&#x000a0;retinal breaks,&#x000a0;rhegmatogenous retinal detachment,&#x000a0;optic neuropathy,&#x000a0;optic atrophy,&#x000a0;macular scar, epiretinal membrane/vitreomacular traction, cystoid macular edema, choroidal neovascularization, complicated cataract, chronic vitritis, macular ischemia, glaucoma, vitreous hemorrhage, and phthisis.<xref ref-type="bibr" rid="article-28457.r64">[64]</xref></p>
      </sec>
      <sec id="article-28457.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Retinitis comprises various inflammatory disorders affecting the retina, often resulting in symptoms such as floaters and diminished visual acuity. Recognizing the signs and dangers of retinitis is crucial, as untreated cases can lead to irreversible vision impairment. The causes of retinitis are diverse, including viral infections&#x000a0;such as CMV or HSV and parasitic and inflammatory conditions. Patients should remain vigilant for changes in their vision, such as new floaters or flashes of light, as these may indicate retinal inflammation. Timely detection and treatment are vital for preventing vision loss and managing retinitis-related complications. Regular eye examinations are essential for individuals at higher risk, such as those with compromised immune systems or a history of ocular inflammation. Patients need to adhere to prescribed treatment regimens and attend follow-up appointments to optimize management and minimize the impact of retinitis on their vision and overall well-being.</p>
      </sec>
      <sec id="article-28457.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Retinitis is an inflammatory condition affecting the retina, often characterized by symptoms such as floaters and decreased visual acuity. This condition can have various underlying causes, including viral infections such as CMV or HSV, parasitic infections, and inflammatory diseases. Retinitis can lead to irreversible vision loss without prompt recognition and management, underscoring the importance of early diagnosis and treatment of both retinitis and the underlying condition.</p>
        <p>Retinitis is not generally responsive to topical treatment. The initial management of noninfectious uveitis posterior to the lens may include observation, and periocular and intraocular glucocorticoid injections. Oral glucocorticoids or additional anti-inflammatory or immunosuppressive agents may be necessary for patients with treatment-resistant symptoms. Infectious retinitis requires initiation of the appropriate antiviral or antibiotic medications prior to the initiation of glucocorticoids.</p>
        <p>In cases where retinitis is secondary to systemic conditions&#x000a0;such as AIDS, syphilis, or autoimmune diseases, primary care physicians, advanced care practitioners, and infectious disease specialists collaborate with ophthalmologists to diagnose and manage the underlying condition effectively. Optometrists also contribute significantly to enhancing healthcare team outcomes in retinitis management. They assist in monitoring patients for vision changes, evaluating treatment responses, and providing supportive care, such as prescribing corrective lenses or low-vision aids to optimize visual function. Pharmacists help monitor potential drug interactions and aid in patient education regarding medications. This interdisciplinary approach ensures comprehensive care that addresses both the ocular and systemic aspects of retinitis, improving overall patient outcomes and quality of life.</p>
      </sec>
      <sec id="article-28457.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28457&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28457">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/retinitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28457">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28457/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28457">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28457.s15">
        <fig id="article-28457.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Cytomegalovirus Retinitis. The image depicts a view of a fundus affected by cytomegalovirus retinitis. National Eye Institute, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/w/index.php?search=Cytomegalovirus+retinitis%2C+Fundus&#x00026;title=Special:MediaSearch&#x00026;go=Go&#x00026;type=image">Public Domain</ext-link>,&#x000a0;via Wikimedia Commons.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1280px-Fundus_photograph-CMV_retinitis_EDA07" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28457.s16">
        <fig id="article-28457.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Toxoplasma Chorioretinitis. The image reveals an active white retinitis lesion temporal to the optic disc. The active lesion is inferiorly adjacent to a pigmented chorioretinal scar. Contributed by K Tripathy, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="toxoplasmosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28457.s17">
        <fig id="article-28457.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Cytomegalovirus and Associated Hemorrhages. The image depicts cytomegalovirus retinitis with characteristic hemorrhages. Contributed by K Tripathy, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cmv__retinitis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28457.s18">
        <fig id="article-28457.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Acute Retinal Necrosis. Retinitis is demonstrated by the peripheral whitish retinal lesions. Typical additional findings include vitreous involvement and a paucity of hemorrhages, as opposed to cytomegalovirus retinitis, which presents with no vitreous involvement and a prominence of hemorrhages. Contributed by K Tripathy, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="arnjpg" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28457.s19">
        <fig id="article-28457.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Post-Fever Retinitis. This image shows macular edema and multiple white retinal lesions. Contributed by K Tripathy, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pfr" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28457.s20">
        <fig id="article-28457.image.f6" position="float" orientation="portrait">
          <caption>
            <p>Subacute Sclerosing Panencephalitis. The image depicts a macular lesion from healed retinitis related to subacute sclerosing panencephalitis. Contributed by K Tripathy, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sspe" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28457.s21">
        <title>References</title>
        <ref id="article-28457.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and treatment of ocular toxoplasmosis.</article-title>
            <source>Korean J Parasitol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>393</fpage>
            <page-range>393-9</page-range>
            <pub-id pub-id-type="pmid">24039281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmichael</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cytomegalovirus and the eye.</article-title>
            <source>Eye (Lond)</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-40</page-range>
            <pub-id pub-id-type="pmid">22173076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Periarterial Plaques (Kyrieleis' Arteriolitis) in a Case of Bilateral Acute Retinal Necrosis.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2017</year>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>251</fpage>
            <page-range>251-252</page-range>
            <pub-id pub-id-type="pmid">26161821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holland</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>The progressive outer retinal necrosis syndrome.</article-title>
            <source>Int Ophthalmol</source>
            <year>1994</year>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>163</fpage>
            <page-range>163-5</page-range>
            <pub-id pub-id-type="pmid">7852023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahendradas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ranganna</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Balu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narayana</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Ocular manifestations associated with chikungunya.</article-title>
            <source>Ophthalmology</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>287</fpage>
            <page-range>287-91</page-range>
            <pub-id pub-id-type="pmid">17631967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Koundanya</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Syphilis Ocular Manifestations</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">32644383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jafri</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Subacute sclerosing panencephalitis - current perspectives.</article-title>
            <source>Pediatric Health Med Ther</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>67</fpage>
            <page-range>67-71</page-range>
            <pub-id pub-id-type="pmid">29985487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khairallah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jelliti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jenzeri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Emergent infectious uveitis.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>225</fpage>
            <page-range>225-38</page-range>
            <pub-id pub-id-type="pmid">20404989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatchette</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Lyme disease: clinical diagnosis and treatment.</article-title>
            <source>Can Commun Dis Rep</source>
            <year>2014</year>
            <month>May</month>
            <day>29</day>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>194</fpage>
            <page-range>194-208</page-range>
            <pub-id pub-id-type="pmid">29769842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diaz</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Sigler</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Rafieetary</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Calzada</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Ocular histoplasmosis syndrome.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-95</page-range>
            <pub-id pub-id-type="pmid">25841248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shrader</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Band</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lauter</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The clinical spectrum of endophthalmitis: incidence, predisposing factors, and features influencing outcome.</article-title>
            <source>J Infect Dis</source>
            <year>1990</year>
            <month>Jul</month>
            <volume>162</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-20</page-range>
            <pub-id pub-id-type="pmid">2355187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Ocular Toxocariasis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35015409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugar</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Jabs</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Danis</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Meinert</surname>
                <given-names>CL</given-names>
              </name>
              <collab>Studies of the Ocular Complications of AIDS Research Group</collab>
            </person-group>
            <article-title>Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>153</volume>
            <issue>6</issue>
            <fpage>1016</fpage>
            <page-range>1016-24.e5</page-range>
            <pub-id pub-id-type="pmid">22310076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCannel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Helm</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Rimmer</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-46</page-range>
            <pub-id pub-id-type="pmid">8554079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonfioli</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Orefice</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Beh&#x000e7;et's disease.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2005</year>
            <season>Jul-Sep</season>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-206</page-range>
            <pub-id pub-id-type="pmid">16282155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muthiah</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Michaelides</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Child</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>91</volume>
            <issue>11</issue>
            <fpage>1452</fpage>
            <page-range>1452-5</page-range>
            <pub-id pub-id-type="pmid">17504853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Panuveitis simulating ocular Beh&#x000e7;et's in cases of chronic myelogenous leukaemia in remission.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>Nov</month>
            <day>23</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">29170182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kariyone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takiguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizushima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kaneoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakane</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Excessive function of peripheral blood neutrophils from patients with Beh&#x000e7;et's disease and from HLA-B51 transgenic mice.</article-title>
            <source>Arthritis Rheum</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>426</fpage>
            <page-range>426-33</page-range>
            <pub-id pub-id-type="pmid">7880197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuiper</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mutis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Jager</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>de Groot-Mijnes</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Rothova</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>152</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-182.e1</page-range>
            <pub-id pub-id-type="pmid">21570674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahn</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YG</given-names>
              </name>
            </person-group>
            <article-title>Intraocular cytokine environment in active Beh&#x000e7;et uveitis.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>142</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-34</page-range>
            <pub-id pub-id-type="pmid">16935587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cytomegaloviral retinitis.</article-title>
            <source>Natl Med J India</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <pub-id pub-id-type="pmid">27492038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanford</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tomlin</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Comyn</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pavesio</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The visual field in toxoplasmic retinochoroiditis.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>89</volume>
            <issue>7</issue>
            <fpage>812</fpage>
            <page-range>812-4</page-range>
            <pub-id pub-id-type="pmid">15965156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Meena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Behera</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Subretinal Hypopyon in Presumed Tubercular Uveitis: A Report of Two Cases.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2018</year>
            <season>Jul-Dec</season>
            <volume>25</volume>
            <issue>3-4</issue>
            <fpage>163</fpage>
            <page-range>163-166</page-range>
            <pub-id pub-id-type="pmid">30765956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Rickettsia retinitis cases in India: a few comments.</article-title>
            <source>J Ophthalmic Inflamm Infect</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">26920002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doft</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Punctate outer retinal toxoplasmosis.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1985</year>
            <month>Sep</month>
            <volume>103</volume>
            <issue>9</issue>
            <fpage>1332</fpage>
            <page-range>1332-6</page-range>
            <pub-id pub-id-type="pmid">4038125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dominguez</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Irvine</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Fundus changes in Behcet's disease.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>1997</year>
            <volume>95</volume>
            <fpage>367</fpage>
            <page-range>367-82; discussion 382-6</page-range>
            <pub-id pub-id-type="pmid">9440180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Bilateral acute retinal necrosis.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1978</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>9</issue>
            <fpage>581</fpage>
            <page-range>581-90</page-range>
            <pub-id pub-id-type="pmid">708676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guex-Crosier</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rochat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Herbort</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Necrotizing herpetic retinopathies. A spectrum of herpes virus-induced diseases determined by the immune state of the host.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>259</fpage>
            <page-range>259-65</page-range>
            <pub-id pub-id-type="pmid">9455742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engstrom</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Muccioli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lindley</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Belfort</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Wolitz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kreiger</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS.</article-title>
            <source>Ophthalmology</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>101</volume>
            <issue>9</issue>
            <fpage>1488</fpage>
            <page-range>1488-502</page-range>
            <pub-id pub-id-type="pmid">8090452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Progressive outer retinal necrosis-like retinitis in immunocompetent hosts.</article-title>
            <source>BMJ Case Rep</source>
            <year>2016</year>
            <month>Aug</month>
            <day>10</day>
            <volume>2016</volume>
            <pub-id pub-id-type="pmid">27511757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <chapter-title>Cherry Red Spot</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">30969663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ormerod</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Dailey</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Ocular manifestations of cat-scratch disease.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-16</page-range>
            <pub-id pub-id-type="pmid">10537781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Successful Management of Proliferative Diabetic Retinopathy and Multiple Choroidal Tubercles in a Patient with Miliary Tuberculosis.</article-title>
            <source>J Ophthalmic Vis Res</source>
            <year>2018</year>
            <season>Apr-Jun</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>210</fpage>
            <page-range>210-211</page-range>
            <pub-id pub-id-type="pmid">29719654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Choroidal tuberculoma.</article-title>
            <source>Natl Med J India</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>106</fpage>
            <pub-id pub-id-type="pmid">27586221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutta Majumder</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Enigma of serpiginous choroiditis.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-333</page-range>
            <pub-id pub-id-type="pmid">30777946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubinsky-Elefant</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>MU</given-names>
              </name>
            </person-group>
            <article-title>Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression of the systemic and ocular forms.</article-title>
            <source>Ann Trop Med Parasitol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-23</page-range>
            <pub-id pub-id-type="pmid">20149289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bergstrom</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Retinal Necrosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">29262034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Simakurthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Endophthalmitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">32644505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mandelcorn</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Infectious causes of posterior uveitis.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-9</page-range>
            <pub-id pub-id-type="pmid">23419296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Temkar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Intralesional antibiotic injection using 41G needle for the management of subretinal abscess in endogenous endophthalmitis.</article-title>
            <source>Int J Retina Vitreous</source>
            <year>2016</year>
            <volume>2</volume>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">27847635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khairallah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kahloun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ben Yahia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jelliti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Messaoud</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>New infectious etiologies for posterior uveitis.</article-title>
            <source>Ophthalmic Res</source>
            <year>2013</year>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>66</fpage>
            <page-range>66-72</page-range>
            <pub-id pub-id-type="pmid">23258387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trehan</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mathai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Moorthy</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic and therapeutic challenge.</article-title>
            <source>Retina</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>180</fpage>
            <page-range>180-3</page-range>
            <pub-id pub-id-type="pmid">19823105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r43">
          <label>43</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Retinal Macroaneurysm</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35015432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farmania</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gulati</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ophthalmic examination as a means to diagnose Subacute Sclerosing Panencephalitis: an optical coherence tomography and ultrawide field imaging evaluation.</article-title>
            <source>Eye Vis (Lond)</source>
            <year>2017</year>
            <volume>4</volume>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">28116334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Serial ultra wide field imaging for following up acute retinal necrosis cases.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2015</year>
            <season>Jan-Apr</season>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-2</page-range>
            <pub-id pub-id-type="pmid">25709284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ancillary investigations in uveitis.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>263</fpage>
            <page-range>263-8</page-range>
            <pub-id pub-id-type="pmid">23803477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holland</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive Committee of the American Uveitis Society.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1994</year>
            <month>May</month>
            <day>15</day>
            <volume>117</volume>
            <issue>5</issue>
            <fpage>663</fpage>
            <page-range>663-7</page-range>
            <pub-id pub-id-type="pmid">8172275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Uveitis in Beh&#x000e7;et's disease.</article-title>
            <source>Int Rev Immunol</source>
            <year>1997</year>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-79</page-range>
            <pub-id pub-id-type="pmid">9203027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alpsoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ba&#x0015f;aran</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Interferon therapy for Beh&#x000e7;et's disease.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>617</fpage>
            <page-range>617-9</page-range>
            <pub-id pub-id-type="pmid">8089288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alpsoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Durusoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ozgurel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ermis</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yazar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basaran</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Interferon alfa-2a in the treatment of Beh&#x000e7;et disease: a randomized placebo-controlled and double-blind study.</article-title>
            <source>Arch Dermatol</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>138</volume>
            <issue>4</issue>
            <fpage>467</fpage>
            <page-range>467-71</page-range>
            <pub-id pub-id-type="pmid">11939808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biron</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Antiviral drugs for cytomegalovirus diseases.</article-title>
            <source>Antiviral Res</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>2-3</issue>
            <fpage>154</fpage>
            <page-range>154-63</page-range>
            <pub-id pub-id-type="pmid">16765457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bakhshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2017</year>
            <season>Sep-Dec</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-252</page-range>
            <pub-id pub-id-type="pmid">29118508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Pau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masur</surname>
                <given-names>H</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
              <collab>National Institutes of Health</collab>
              <collab>HIV Medicine Association of the Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2009</year>
            <month>Apr</month>
            <day>10</day>
            <volume>58</volume>
            <issue>RR-4</issue>
            <fpage>1</fpage>
            <page-range>1-207; quiz CE1-4</page-range>
            <pub-id pub-id-type="pmid">19357635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vishnevskia-Dai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shapira</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rahav</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shimoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Somech</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moisseiev</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cytomegalovirus retinitis in HIV-negative patients: a practical management approach.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>866</fpage>
            <page-range>866-868.e3</page-range>
            <pub-id pub-id-type="pmid">25556113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Current treatment of ocular toxoplasmosis in immunocompetent patients: a network meta-analysis.</article-title>
            <source>Acta Trop</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>185</volume>
            <fpage>52</fpage>
            <page-range>52-62</page-range>
            <pub-id pub-id-type="pmid">29704469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de-la-Torre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stanford</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Gomez-Marin</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Therapy for ocular toxoplasmosis.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>314</fpage>
            <page-range>314-20</page-range>
            <pub-id pub-id-type="pmid">21970662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soheilian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sadoughi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ghajarnia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dehghan</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Yazdani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Behboudi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Anisian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peyman</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis.</article-title>
            <source>Ophthalmology</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>112</volume>
            <issue>11</issue>
            <fpage>1876</fpage>
            <page-range>1876-82</page-range>
            <pub-id pub-id-type="pmid">16171866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saxena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Phuljhele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kalaiselvan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Karna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lodha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>69</volume>
            <issue>12</issue>
            <fpage>3734</fpage>
            <page-range>3734-3739</page-range>
            <pub-id pub-id-type="pmid">34827033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kokkada</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Barthakur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palaian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chhetri</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ocular side effects of antitubercular drugs - a focus on prevention, early detection and management.</article-title>
            <source>Kathmandu Univ Med J (KUMJ)</source>
            <year>2005</year>
            <season>Oct-Dec</season>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>438</fpage>
            <page-range>438-41</page-range>
            <pub-id pub-id-type="pmid">16449853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tam</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lightman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antiviral selection in the management of acute retinal necrosis.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2010</year>
            <month>Feb</month>
            <day>02</day>
            <volume>4</volume>
            <fpage>11</fpage>
            <page-range>11-20</page-range>
            <pub-id pub-id-type="pmid">20169044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aizman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Elner</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Treatment of acute retinal necrosis syndrome with oral antiviral medications.</article-title>
            <source>Ophthalmology</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>114</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-12</page-range>
            <pub-id pub-id-type="pmid">17123607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huynh</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Comer</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Vitreous penetration of orally administered valacyclovir.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>145</volume>
            <issue>4</issue>
            <fpage>682</fpage>
            <page-range>682-6</page-range>
            <pub-id pub-id-type="pmid">18226802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blumenkranz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Culbertson</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Clarkson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Dix</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment of the acute retinal necrosis syndrome with intravenous acyclovir.</article-title>
            <source>Ophthalmology</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>296</fpage>
            <page-range>296-300</page-range>
            <pub-id pub-id-type="pmid">3703498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28457.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Temkar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sagar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pushker</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
            </person-group>
            <article-title>Phthisis Bulbi-a Clinicopathological Perspective.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2018</year>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>788</fpage>
            <page-range>788-803</page-range>
            <pub-id pub-id-type="pmid">29902388</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
